Researchers in Brussels uncover important new clues for future cancer immunotherapies
Share article:
Share article:

Researchers in Brussels uncover important new clues for future cancer immunotherapies

Photo by Michael Longmire on Unsplash

A group of researchers with the University of Brussels (VUB) has mapped the immune landscape of glioblastoma tumours – progress that will hopefully uncover ways to make cancer treatments more effective.

The research comes from a team led by Professors Kiavash Movahedi and Jo Van Ginderachter, who worked in collaboration with colleagues from VIB (Flemish Institute for Biotechnology), VUB, and KU Leuven.

“We’re interested in cancer research, and in understanding how tumours progress,” Professor Movahedi told The Brussels Times. “You have to consider a tumour as a very complex, organlike structure.”

“It’s not only cancer cells, but a whole range of other normal host cells that comprise a tumour. It’s this whole ecosystem, this whole set of interactions, that determines whether tumours grow or are rejected as they develop.”

The team of scientists set out to map those parts of a tumour, and in doing so made a number of discoveries along the way.

One of those was the striking diversity of macrophages, which are specialised cells involved in the detection and destruction of harmful organisms, like a tumour.

“The detailed insight into the complexity of the macrophage compartment in tumours is thrilling,” said Professor Van Ginderachter. “It will be exciting to discover how different types of macrophages exactly act within glioblastoma tumours and how we can translate this knowledge into directed therapies.”

By examining tumours in both mice and humans, they also learned that the two are remarkably similar, which further expands the potential for testing new cancer treatments.

“What’s exciting is moving this to the next step where we try to find molecular switches, ways to actually make these macrophages highly anti-tumour, to activate them so they now start attacking the cancer cells and helping other immune cells to destroy the tumour,” said Professor Movahedi.

Related News


Human glioblastoma tumours like the ones they work with are aggressive, hard-to-treat brain cancers that have a high unmet need for new treatment options.

While immunotherapy can be effective at treating some cancers (for example, melanoma), it rarely works with these ones, and is far from a one-size-fits-all. Mapping out a tumour’s immune cells could potentially help scientists create personalised treatment plans.

Doctors and scientists don’t always know why a cancer treatment works in some patients but not others. One hypothesis is that it comes down to those newly mapped immune cells.

Using the information gleaned from those can help predict which patients will respond to which treatments.

“Macrophages are the next frontier in cancer immunotherapy,” Professor Movahedi said. “They can either promote or block tumour growth. In glioblastoma, these cells are present in high numbers and unfortunately stimulate tumour growth. Our intent is to find a molecular switch that pushes them in the right direction by turning them into toxic cells that attack the tumour.”

Their progress is the result of four years of work, and the researchers are hopeful the new findings will provide a basis for developing new immunotherapeutic approaches for these aggressive brain tumours.

The researchers’ findings were published in Nature Neuroscience.

Helen Lyons
The Brussels Times

Latest news

EU auditors: More worried about the future budget than about pervasive errors in the 2020 budget
The European Court of Auditors (ECA) have signed off the 2020 EU accounts as giving a true and fair view of the union’s financial position but like ...
Belgium aims to tackle sexual violence with video interrogations
The federal government is looking to tackle sexual violence and increase convictions connected to this crime by relying more heavily on video ...
Duvel celebrates 150th anniversary with special brew in commemorative bottle
Belgium’s Duvel Moortgat Brewery is celebrating its 150th anniversary with the release of a special brew in a commemorative bottle shaped like its ...
Pollution scandal: 3M to show emissions don’t pose risk or halt production
Flanders has ordered American company 3M, involved in a pollution scandal in Antwerp, to prove that emissions linked to its production activities do ...
The Netherlands fears a greater rise in sea levels than forecast
Sea levels could rise by up to two metres by 2100 on the Dutch coastline – far more than previously forecast – according to an announcement from the ...
The Smurfs return to Belgian TV with the first new show since 1989
A new Smurfs show is bringing the characters of Belgium's second-most-famous comic franchise back to the small screen with their first new series, 30 ...
Almost half of Belgian subsidies from EU left unused
Belgium left almost half (49%) of its subsidies allocated by the European Union between 2013 and 2020 unused, the equivalent of around €1.375 ...
Visitors to embark on Orient Express adventure at Brussels exhibition
An exhibition dedicated to the Orient Express – the train that was the scene for many novels, including Agatha Christie's – allows visitors to ...
Offers for fake Covid Safe Tickets circulating on social media
As the Covid Safe Ticket (CST) becomes mandatory in many places across Belgium, offers for forgeries are increasingly circulating on social media. ...
Belgium in Brief: Feeling Good/ Pandemic Law
Yesterday I said I was writing a newsletter I didn't want to write again. Today I'm writing another one ahead of a meeting that wasn't supposed ...
Eating less meat won’t actually help much with Flemish CO2 emissions
When it comes to the ways in which ordinary people can help to reduce CO2 emissions, eating less meat is often touted as an important solution. ...
At least one in seven coronavirus patients suffers from long-term Covid
Six months after becoming infected with the coronavirus, at least one in seven people still show symptoms connected to the infection, varying from ...